OVA1 – Ovarian Cancer Blood Test

Don’t leave your health in the hands of others!

OVA1 – Ovarian Cancer Blood Test

Now Available

The Ovarian Cancer National Alliance believes it is important to inform the community of the following information:

A new risk assessment test for ovarian cancer, OVA1, is now available. Vermillion’s OVA1 test, available only through Quest Diagnostics, Inc., is the first blood test approved by the U.S. Food and Drug Administration (FDA) to help physicians determine the likelihood that a woman’s ovarian mass is cancerous or not, prior to a planned surgery.

OVA1 measures the levels of five protein biomarkers in a woman’s blood to determine the likelihood of cancer. Approximately 20 percent of women with pelvic masses have cancer, but the proportion rises with age.

The results of the test may help a physician decide the type of surgeon who should operate on a patient with a pelvic mass. Data shows that women with ovarian cancer who have their surgeries performed by a gynecologic oncologist fare better, however many women have their initial surgery performed by a gynecologist.

OVA1 is not a screening test for ovarian cancer.

A physician should use the test along with clinical exams and other tests.

About OVA1®

OVA1 is the first test cleared by FDA for aiding in the pre-surgical evaluation of a woman’s ovarian mass for cancer, and also is the first protein-based In Vitro Diagnostic Multi-Variate Index Assays (IVDMIA), a new class of state of the art software-based diagnostics. The test utilizes five well-established biomarkers — Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) — and proprietary software to determine the likelihood of malignancy in women with ovarian mass for whom surgery is planned.

OVA1 is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. It is an aid to further assess the likelihood that malignancy is present when the physician’s independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis. ~ Source: Quest Diagnostics

For more information:

www.QuestDiagnostics.com/womenscancer  w

F.D.A. Approved

This information was found by Fran Drescher, Cancer Schmancer Movement.

www.cancerschmancer.org

Don’t forget to check out cancerschmancer.org !

The site has been renovated and contains tons of information to educate and advocate women’s health issues.